Healthcare & Life Sciences

The Netherlands: Europe’s Most Attractive Life Sciences Hotspot, or the Next Big Troublemaker?

July 1, 2019
Healthcare & Life SciencesPublic & Government Affairs

The Netherlands certainly has a lot going for it when it comes to attracting the world’s leading biopharmaceutical companies: World-class research institutes, a well-respected healthcare system and not least of all the new home of the European Medicines Agency.

FTI Consulting Brussels and IvCB explore whether there is another side to the story. Read more here- A New Healthcare Hotspot?

Related Articles

4th Annual Shareholder Activism State of the Market

September 8, 2025—Shareholder Activism State of the Market – 2025 Request Report The Shareholder Activism State of the Market –...
Use It or Lose It: U.S. Hydrogen Industry Must Act To Maintain Momentum

July 12, 2025—Key takeaway: Following the passage of the “One Big Beautiful Bill Act”, time is of the essence for hydrogen produce...
Quick Analysis: ‘One Big Beautiful Bill’ Drives More Gas and Batteries, Less Renewables

July 3, 2025—With the recent passage of the “One Big Beautiful Bill” (“OBBB” or the “Legislation”),[1] FTI Consulting’s...
FTI Consulting News Bytes – 24 July 2026

July 24, 2026—FTI Consulting News Bytes This week, we kick off with news coming out of the annual Farnborough International Airshow, w...
ESG+ Newsletter – 23 July 2026

July 23, 2026—We open this week’s ESG+ with EFRAG’s 2026 State of Play Report, which examines the disclosures of over 900 ...
ESG Reporting Strategy in 2026

July 23, 2026—On July 3, the European Commission adopted the revised European Sustainability Reporting Standards (ESRS) as part of the...